Jean-Michel Nguyen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1828351/publications.pdf

Version: 2024-02-01

78 papers

3,339 citations

172457
29
h-index

56 g-index

83 all docs 83 docs citations

83 times ranked 5091 citing authors

#	Article	IF	CITATIONS
1	Colonic inflammation in Parkinson's disease. Neurobiology of Disease, 2013, 50, 42-48.	4.4	482
2	Prospective Evaluation of Magnetic Resonance Imaging and [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. Journal of Clinical Oncology, 2017, 35, 2911-2918.	1.6	247
3	Bilateral Deep Brain Stimulation of the Globus Pallidus to Treat Tardive Dyskinesia. Archives of General Psychiatry, 2007, 64, 170.	12.3	178
4	Intracoronary autologous mononucleated bone marrow cell infusion for acute myocardial infarction: results of the randomized multicenter BONAMI trial. European Heart Journal, 2011, 32, 1748-1757.	2.2	158
5	High Resolution Colonoscopy With Chromoscopy Versus Standard Colonoscopy for the Detection of Colonic Neoplasia: A Randomized Study. Clinical Gastroenterology and Hepatology, 2006, 4, 349-354.	4.4	134
6	Autologous myoblast transplantation after myocardial infarction increases the inducibility of ventricular arrhythmias. Cardiovascular Research, 2006, 69, 348-358.	3.8	116
7	Diuretic and Enhanced Sodium Restriction Results in Improved Antiproteinuric Response to RAS Blocking Agents. Journal of the American Society of Nephrology: JASN, 2005, 16, 474-481.	6.1	113
8	Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunology, Immunotherapy, 2002, 51, 539-546.	4.2	99
9	Propranolol for treatment of ulcerated infantile hemangiomas. Journal of the American Academy of Dermatology, 2011, 64, 827-832.	1.2	98
10	Progressive Cardiac Conduction Defect is the Prevailing Phenotype in Carriers of a Brugada Syndrome <i>SCN5A</i> Mutation. Journal of Cardiovascular Electrophysiology, 2006, 17, 270-275.	1.7	90
11	Prospective Multicenter Study of Pegylated Liposomal Doxorubicin Treatment in Patients With Advanced or Refractory Mycosis Fungoides or Sézary Syndrome. Archives of Dermatology, 2008, 144, 727-33.	1.4	88
12	Use of Smartphones for Early Detection of Melanoma: Systematic Review. Journal of Medical Internet Research, 2018, 20, e135.	4.3	84
13	Improvement of psychometric properties of a scale measuring inpatient satisfaction with care: a better response rate and a reduction of the ceiling effect. BMC Health Services Research, 2007, 7, 197.	2.2	76
14	Vemurafenib: an unusual <scp>UVA</scp> â€induced photosensitivity. Experimental Dermatology, 2013, 22, 297-298.	2.9	76
15	Familial Aggregation of Calcific Aortic Valve Stenosis in the Western Part of France. Circulation, 2006, 113, 856-860.	1.6	74
16	Treatment of Metastatic Melanoma with Autologous Melan-A/Mart-1-Specific Cytotoxic T Lymphocyte Clones. Journal of Investigative Dermatology, 2009, 129, 2835-2842.	0.7	73
17	Prospective evaluation of quality of life (SF-36v2) and nonspecific symptoms before and after cure of primary hyperparathyroidism (1-year follow-up). Surgery, 2007, 141, 153-160.	1.9	72
18	Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia. Neurology, 2016, 86, 651-659.	1.1	61

#	Article	IF	CITATIONS
19	Efficacy of cetuximab in the treatment of squamous cell carcinoma. Journal of Dermatological Treatment, 2014, 25, 424-427.	2.2	54
20	Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunology, Immunotherapy, 2007, 56, 1853-1860.	4.2	50
21	Osteointegration of femoral stem prostheses with a bilayered calcium phosphate coating. Biomaterials, 2006, 27, 1119-1128.	11.4	42
22	Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy. Clinical Neurology and Neurosurgery, 2016, 146, 35-39.	1.4	41
23	Is a Single BRAF Wild-Type Test Sufficient to Exclude Melanoma Patients from Vemurafenib Therapy?. Journal of Investigative Dermatology, 2014, 134, 1468-1470.	0.7	37
24	Different cutaneous innate immunity profiles in acne patients with and without atrophic scars. European Journal of Dermatology, 2016, 26, 68-74.	0.6	37
25	Risk factors for chronic rejection in pediatric renal allograft recipients. Pediatric Nephrology, 1996, 10, 723-727.	1.7	34
26	Clinical significance of <scp>BRAF</scp> mutation status in circulating tumor <scp>DNA</scp> of metastatic melanoma patients at baseline. Experimental Dermatology, 2016, 25, 783-788.	2.9	34
27	CCL2, Galectin-3, and SMRP Combination Improves the Diagnosis of Mesothelioma in Pleural Effusions. Journal of Thoracic Oncology, 2012, 7, 883-889.	1.1	33
28	Evidence of a non-linear influence of patient age on satisfaction with hospital care. International Journal for Quality in Health Care, 2007, 19, 382-389.	1.8	32
29	Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma. Acta Dermato-Venereologica, 2018, 98, 406-410.	1.3	31
30	Development of an individual score for melanoma risk. European Journal of Cancer Prevention, 2011, 20, 217-224.	1.3	30
31	Effects of perioperative intravenous low dose of ketamine on postoperative analgesia in children. European Journal of Anaesthesiology, 2010, 27, 47-52.	1.7	26
32	Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration. Nephrology Dialysis Transplantation, 2010, 25, 2218-2224.	0.7	26
33	Non-homogeneous effect of levodopa on inhibitory circuits in Parkinson's disease and dyskinesia. Parkinsonism and Related Disorders, 2013, 19, 165-170.	2.2	26
34	Targeted Melanoma Prevention Intervention: A Cluster Randomized Controlled Trial. Annals of Family Medicine, 2014, 12, 21-28.	1.9	26
35	Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing) Tj ETQq1	1 0.78431 4.2	4 rgBT /Ov€ 26
36	Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival. Journal of Immunology Research, 2014, 2014, 1-10.	2.2	25

#	Article	IF	CITATIONS
37	DECREASED CYTOTOXIC ACTIVITY OF NATURAL KILLER CELLS IN KIDNEY ALLOGRAFT RECIPIENTS TREATED WITH HUMAN HLA-DERIVED PEPTIDE. Transplantation, 1997, 63, 1004-1011.	1.0	25
38	Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients. Journal of Immunology Research, 2018, 2018, 1-10.	2.2	23
39	TLR expression in human melanoma cells. European Journal of Dermatology, 2011, 21, 899-905.	0.6	22
40	Absence of modulation of CD4+CD25 ^{high} regulatory T cells in CTCL patients treated with bexarotene. Experimental Dermatology, 2010, 19, e95-102.	2.9	20
41	Random forest of perfect trees: concept, performance, applications and perspectives. Bioinformatics, 2021, 37, 2165-2174.	4.1	20
42	Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial. Blood, 2015, 126, 395-395.	1.4	20
43	Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive. European Journal of Dermatology, 2015, 25, 452-456.	0.6	19
44	Prospective trial on a school-based skin cancer prevention project. European Journal of Cancer Prevention, 2009, 18, 133-144.	1.3	18
45	Creation and test of a questionnaire for self-assessment of melanoma risk factors. European Journal of Cancer Prevention, 2010, 19, 48-54.	1.3	16
46	Caval Incorporation of the LGM Vena Tech Filter: An Experimental Study. Journal of Vascular and Interventional Radiology, 1997, 8, 419-425.	0.5	14
47	Efficacy and safety of nivolumab in metastatic melanoma: real-world practice. European Journal of Dermatology, 2019, 29, 315-321.	0.6	14
48	Defective activations of STAT3 Ser727 and PKC isoforms lead to oncostatin M resistance in metastatic melanoma cells. Journal of Pathology, 2009, 217, 665-676.	4.5	13
49	About the cutaneous targets of bexarotene in CTCL patients. Experimental Dermatology, 2010, 19, e299-301.	2.9	12
50	Proposal for an annual skin examination by a general practitioner for patients at high risk for melanoma: a French cohort study. BMJ Open, 2015, 5, e007471.	1.9	12
51	Tissue prognostic markers for adoptive immunotherapy in melanoma. European Journal of Dermatology, 2007, 17, 295-301.	0.6	12
52	CICAFAST: comparison of a biological dressing composed of fetal fibroblasts and keratinocytes on a split-thickness skin graft donor site versus a traditional dressing: a randomized controlled trial. Trials, 2019, 20, 612.	1.6	11
53	Is There Any Need for Expanding the Perineural Space Before Catheter Placement in Continuous Femoral Nerve Blocks?. Regional Anesthesia and Pain Medicine, 2006, 31, 393-400.	2.3	10
54	Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trial. Cancer Immunology, Immunotherapy, 2020, 69, 1663-1672.	4.2	10

#	Article	IF	Citations
55	Effects of lumbar artificial disc design on intervertebral mobility: in vivo comparison between mobile-core and fixed-core. European Spine Journal, 2012, 21, 630-640.	2.2	9
56	PD‣1 expression by tumor cell lines: A predictive marker in melanoma. Experimental Dermatology, 2018, 27, 647-655.	2.9	9
57	Adult acne in women is not associated with a specific type of Cutibacterium acnes. Journal of the American Academy of Dermatology, 2019, 81, 851-852.	1.2	9
58	Comparison of gastric emptying scintigraphy based on the geometric mean of the gastric proportion of the abdominal radioactivity or on the geometric mean of the intragastric radioactivity. Nuclear Medicine Communications, 2006, 27, 431-437.	1.1	8
59	A recall program for the outcome of conventional root canal treatment performed in a teaching hospital. Acta Odontologica Scandinavica, 2013, 71, 1399-1409.	1.6	8
60	Assessing the extirpative quality of a radical prostatectomy technique: categorisation and mapping of technical errors. BJU International, 2014, 114, 522-531.	2.5	8
61	Immunohistochemical markers of advanced basal cell carcinoma: CD56 is associated with a lack of response to vismodegib. European Journal of Dermatology, 2016, 26, 452-459.	0.6	8
62	Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial. Blood, 2014, 124, 3359-3359.	1.4	8
63	Hypnotic prescription without face to face contact: A report from French family medicine. European Journal of General Practice, 2013, 19, 158-161.	2.0	7
64	Younger age at the time of first metastasis in BRAF-mutated compared to BRAF wild-type melanoma patients. Oncology Reports, 2014, 32, 808-814.	2.6	6
65	Change in lentigo maligna score assessed by inÂvivo reflectance confocal microscopy after 1Âmonth of imiquimod treatment for lentigo maligna management. Journal of the American Academy of Dermatology, 2022, 86, 1042-1048.	1.2	5
66	Tissue Biomarkers in Melanoma Patients Treated with TIL. PLoS ONE, 2012, 7, e48729.	2.5	4
67	Inclusion of populations at risk of advanced melanoma in an opportunistic targeted screening project involving general practitioners. Scandinavian Journal of Primary Health Care, 2016, 34, 286-294.	1.5	4
68	Impact of the time interval between lymph node recurrence and lymphadenectomy on melanoma patient survival. European Journal of Dermatology, 2017, 27, 166-173.	0.6	3
69	Cardiac adverse events associated with anti-PD-1 therapy in patients treated for advanced melanoma: relevance of dosing troponin T levels. European Journal of Dermatology, 2021, 31, 205-212.	0.6	3
70	Positive margins after surgical excision of locoregional cutaneous melanoma metastasis and their impact on patient outcome. European Journal of Dermatology, 2018, 28, 661-667.	0.6	3
71	Viral DNA contamination is responsible for Epstein–Barr virus detection in cytotoxic T lymphocytes stimulated in vitro with Epstein–Barr virus B-lymphoblastoid cell line. Cancer Immunology, Immunotherapy, 2010, 59, 1867-1875.	4.2	2
72	Why We Should Focus on Melanoma-Targeted Screening Strategies. Dermatology, 2017, 233, 480-481.	2.1	2

#	Article	IF	CITATIONS
73	Factors Related to Prostate-Specific Antigen–Based Prostate Cancer Screening in Primary Care: Retrospective Cohort Study of 120,587 French Men Over the Age of 50 Years. JMIR Public Health and Surveillance, 2018, 4, e10352.	2.6	2
74	Management of adjuvant settings for Stage III melanoma patients in France prior to checkpoint inhibitors: epidemiological data from the RIC-Mel database. European Journal of Dermatology, 2020, 30, 389-396.	0.6	1
75	Effect of Physician Notification Regarding Nonadherence to Colorectal Cancer Screening on Early Cancer Detection. JAMA - Journal of the American Medical Association, 2020, 323, 2429.	7.4	1
76	Self Expending Metallic Stents (SEMS) with Antireflux Valve for Distal Esophageal Carcinoma: Results of a Randomized Trial. Gastrointestinal Endoscopy, 2006, 63, AB241.	1.0	0
77	Targeted screening for melanoma after a 5-year follow-up: Comparison of melanoma incidence and lesion thickness at diagnosis in screened (versus unscreened) patients. La Presse M©dicale Open, 2021, 2, 100013.	0.4	O
78	Detection of BRAF mutations in the plasma of melanoma patients as an early marker of treatment efficiency Journal of Clinical Oncology, 2014, 32, 9069-9069.	1.6	0